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We appreciate the reply by Hasenkrug et al. The basic issue we addressed in ourpaper was whether the differences between the different interferon alpha (IFN-)
subtypes are quantitative or qualitative. In our paper, we noted that all of the IFN-
subtypes are able to inhibit HIV replication in various primary cell types to the same
extent, depending upon the dose given (1). Furthermore, we presented a limited data
set of IFN-stimulated genes (ISGs) which were quite similar irrespective of the distinct
IFN- subtype added to the cell culture. On the basis of these ﬁndings, we concluded
that IFN- subtypes do not induce different biological responses. In other words, the
difference between IFN- subtypes in relation to HIV replication inhibition is quantita-
tive and not qualitative. Hasenkrug et al. came to a different conclusion in their work
(2, 3), i.e., that distinct IFN- subtypes, among others, IFN-6, IFN-8, and IFN-14, have
a more potent anti-HIV activity than other subtypes and that the differences are related
to distinct biological activities. While they showed in Fig. 1 of their work that IFN-14
had a higher level of potency (11-fold) than IFN-2 (in line with its higher receptor
binding afﬁnity and antiviral activity against vesicular stomatitis virus [VSV; 4]), all other
experiments were done at one IFN- concentration. From that point, they concluded
that the differences between IFN-2 and IFN-14 are qualitative, while they themselves
showed that the differences are actually quantitative and are related to receptor
binding afﬁnity (3, 4).
IFN- subtypes have distinct afﬁnities to the IFN receptor (4), and there is a
consensus that level of afﬁnity determines the strength of signaling. Moll et al. also
reported that differences in ISG levels were only seen at subsaturating levels (5). Thus,
we are challenged when studying IFN- subtypes in whether we should design
experiments comparing IFN- subtypes using equimolar doses or functional units and
at what dose(s). Data generated with identical functional units of distinct IFN-
subtypes may rather reﬂect the higher potency of a given IFN- subtype as assessed in
a ﬁrst round of experimentation for determining the functional units. In the end, we are
convinced that we need stringent in vitro as well as in vivo dose-response investigations
to compare IFN- subtypes.
Furthermore, Lavender et al. argued in their paper that they had chosen a high dose
of IFN-2 to demonstrate the maximal efﬁcacy that would be clinically achievable by
IFN-2 compared to the same unit dose of IFN-14 (2). This argument is problematic.
First, we do not know to what extent the same unit dose of IFN-14 is tolerated in
human or mice, as we lack such data. Second, and more important, the half-life of
proteins in mice is much shorter than in humans; thus, the same (weight-adjusted) dose
in mice would have a lesser effect than in humans, and higher weight-adjusted doses
are therefore required in mice. At the least, it appears that the humanized mice showed
good tolerance of the dose used by Lavender et al., but let us remember that IFNs are
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species speciﬁc and that humanized mice will most likely not be the model used to
explore undesirable side-effects of IFNs.
We entirely agree that in vitro experiments must be followed by in vivo experiments.
We highly appreciate the data presented by Lavender et al. (2). We also entirely agree
that IFNs may act differently with cell type-speciﬁc responses in the microenvironment
and that this can hardly be recapitulated by in vitro experiments. Furthermore, phar-
macological doses of IFNs administered exogenously may have biological activities that
are distinct from those of IFNs released in the microenvironment. From our point of
view, the chapter on IFN subtypes (and, in particular, whether they have distinct
biological activities) is not closed.
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